Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.62 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081031 | 1.00 | ACE (0.66) | ACEHRH4MMETAAR1SLC6A2 | |
| SCHEMBL3081033 | 1.00 | ACE (0.66) | ACEHRH4MMETAAR1SLC6A2 | |
| Fasidotril SCHEMBL7301419 | 0.86 | ACE (0.88) | ACEHRH4MMEALDH1A1CYP2D6 | |
| Fasidotril SCHEMBL49006 | 0.86 | ACE (0.88) | ACEHRH4MMEALDH1A1CYP2D6 | |
| SCHEMBL5913277 | 0.86 | HRH4 (0.62) | ACEHRH4TAAR1SLC6A2SLC6A4 | |
| SCHEMBL5913510 | 0.86 | HRH4 (0.62) | ACEHRH4TAAR1SLC6A2SLC6A4 | |
| SCHEMBL8691873 | 0.86 | HRH4 (0.62) | ACEHRH4TAAR1SLC6A2SLC6A4 | |
| SCHEMBL8861655 | 0.84 | MME (0.62) | ACEMMETAAR1SLC6A2SLC6A4 | |
| SCHEMBL8861615 | 0.84 | MME (0.62) | ACEMMETAAR1SLC6A2SLC6A4 | |
| SCHEMBL30569656 | 0.84 | MME (0.62) | ACEMMETAAR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767921-B2 | BENZYL (S,S)-2-(2-ACETYLSULPHANYLMETHYL-3-BENZO(1,3)DIOXOL-5-YLPROPIONYL -AMINO)PROPIONATE; DIFFERENTIAL SCANNING CALORIMETRY; FOR TREATMENT OF HYPERTENSION/CARDIOVASCULAR SYSTEM DISORDERS | BIOPROJECT (FR) | 2004-07-27 | — | — | US | claimed |
| US-20030203965-A1 | Polymorphic forms of fasidotril, their methods of preparation and pharmaceutical compositions comprising them | BIOPROJECT (FR) | 2003-10-30 | — | — | US | claimed |
| EP-1348703-A1 | Polymorph forms of fasidotril, their processes of preparation and pharmaceutical compositions containing them | BIOPROJET (FR) | 2003-10-01 | — | — | EP | claimed |
| US-20100234393-A1 | USE OF A VASOPEPTIDASE INHIBITOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | BIOPROJET (FR) | 2010-09-16 | — | — | US | disclosed |
| US-6767921-B2 | BENZYL (S,S)-2-(2-ACETYLSULPHANYLMETHYL-3-BENZO(1,3)DIOXOL-5-YLPROPIONYL -AMINO)PROPIONATE; DIFFERENTIAL SCANNING CALORIMETRY; FOR TREATMENT OF HYPERTENSION/CARDIOVASCULAR SYSTEM DISORDERS | BIOPROJECT (FR) | 2004-07-27 | — | — | US | disclosed |
| US-6767921-B2 | BENZYL (S,S)-2-(2-ACETYLSULPHANYLMETHYL-3-BENZO(1,3)DIOXOL-5-YLPROPIONYL -AMINO)PROPIONATE; DIFFERENTIAL SCANNING CALORIMETRY; FOR TREATMENT OF HYPERTENSION/CARDIOVASCULAR SYSTEM DISORDERS | BIOPROJECT (FR) | 2004-07-27 | — | — | US | disclosed |
| US-20030203965-A1 | Polymorphic forms of fasidotril, their methods of preparation and pharmaceutical compositions comprising them | BIOPROJECT (FR) | 2003-10-30 | — | — | US | disclosed |
| US-20030203965-A1 | Polymorphic forms of fasidotril, their methods of preparation and pharmaceutical compositions comprising them | BIOPROJECT (FR) | 2003-10-30 | — | — | US | disclosed |
| JP-2003300974-A | POLYMORPHISM FORM OF FASIDOTRIL, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIOPROJET | 2003-10-21 | — | — | JP | disclosed |
| EP-1348703-A1 | Polymorph forms of fasidotril, their processes of preparation and pharmaceutical compositions containing them | BIOPROJET (FR) | 2003-10-01 | — | — | EP | disclosed |
| EP-1348703-A1 | Polymorph forms of fasidotril, their processes of preparation and pharmaceutical compositions containing them | BIOPROJET (FR) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203965-A1 | Polymorphic forms of fasidotril, their methods of preparation and pharmaceutical compositions comprising them | CYP4B1, CYP2S1, CYP3A4 | ACE 1809/4885HRH4 1556/4885MME 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.